구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Emicizumab (Emicizumab) Indiana Hemophilia &Thrombosis Cen…·Factor VIII Deficiency, Congenital 45 trials |
|---|---|
Overview Program | Emicizumab |
Overview Company | Indiana Hemophilia &Thrombosis Center, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Factor VIII Deficiency, Congenital |
Overview Indication | Haemophilic Pseudotumour |
Overview Phase | APPROVED |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
MoA Mechanism | Targeted rebalancing agents enhance coagulation by attenuating endogenous anticoagulants such as tissue factor pathway |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | [Evaluation of the efficacy and safety of reduced-dose emicizumab in infants with severe hemophilia A: a single-center real-world study].. To investigate the efficacy and safety of reduced-dose emicizumab (EMI) prophylaxis in infants under one year of age with severe hemophilia A (HA). Medical records of 11 infants aged ≤12 months with severe HA who received reduced-dose EMI in the Departme… |
Clinical Safety signal | [Evaluation of the efficacy and safety of reduced-dose emicizumab in infants with severe hemophilia A: a single-center real-world study].. To investigate the efficacy and safety of reduced-dose emicizumab (EMI) prophylaxis in infants under one year of age with severe hemophilia A (HA). Medical records of 11 infants aged ≤12 months with severe HA who received reduced-dose EMI in the Departme… |
Clinical Result source | ClinicalTrials.gov NCT03380780 |
Clinical Program phase | APPROVED |
Clinical Trial ref | NCT03380780 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Emicizumab (Emicizumab) Indiana Hemophilia &Thrombosis Cen…·Factor VIII Deficiency, Congenital 45 trials |
|---|---|
Overview Program | Emicizumab |
Overview Company | Indiana Hemophilia &Thrombosis Center, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Factor VIII Deficiency, Congenital |
Overview Indication | Haemophilic Pseudotumour |
Overview Phase | APPROVED |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
MoA Mechanism | Targeted rebalancing agents enhance coagulation by attenuating endogenous anticoagulants such as tissue factor pathway |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | [Evaluation of the efficacy and safety of reduced-dose emicizumab in infants with severe hemophilia A: a single-center real-world study].. To investigate the efficacy and safety of reduced-dose emicizumab (EMI) prophylaxis in infants under one year of age with severe hemophilia A (HA). Medical records of 11 infants aged ≤12 months with severe HA who received reduced-dose EMI in the Departme… |
Clinical Safety signal | [Evaluation of the efficacy and safety of reduced-dose emicizumab in infants with severe hemophilia A: a single-center real-world study].. To investigate the efficacy and safety of reduced-dose emicizumab (EMI) prophylaxis in infants under one year of age with severe hemophilia A (HA). Medical records of 11 infants aged ≤12 months with severe HA who received reduced-dose EMI in the Departme… |
Clinical Result source | ClinicalTrials.gov NCT03380780 |
Clinical Program phase | APPROVED |
Clinical Trial ref | NCT03380780 |
추천 비교
추천 비교